Volume 1, Issue 12
Editorialp. 1601
Personalized medicine in non-smallcell lung cancer: has it come of age?
Author(s): Martin Sebastian, Martin Reck
News and Viewsp. 1605–160
Promising results for new influenza drug presented at the Infectious Diseases Society of America Annual Meeting
Research Articlep. 1609
Experience in international clinical research: the HIV Prevention Trials Network
Author(s): Nirupama Deshmane Sista, Quarraisha Abdool Karim, Kathy Hinson, Deborah Donnell, Susan H Eshleman,Sten H ermund
Review: Clinical Trail Outcomesp. 1619
Assessing nocturia in clinical trials
Author(s): Svetlana Avulova , Jeffrey P Weiss
Clinical Trail Outcomesp. 1627
Design of clinical trials for biomarker research in oncology
Author(s): Sumithra J Mandrekar, Daniel J Sargent
Patient Perspectivep. 1637
miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma
Author(s): Krishan Jethwa, Jun Wei, Kayla McEnery,Amy B Heimberger
Therapeutic Prospectivep. 1651
Anti-angiogenic therapy for prostate cancer: rationale and ongoing trials
Author(s): Bamidele A Adesunloye, William L Dahut
Research Articlep. 1663
Incentives and barriers to neurological clinical research participation
Author(s): Anne S Lindblad, Pam Zingeser, Nil Sismanyazici-Navaie
Review Articlep. 1669
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Author(s): Eva Baroke, Shyam Maharaj, Martin Kolb
Review Articlep. 1681
JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data
Author(s): Raoul Tibes, Ruben Mesa
Review Articlep. 1695
Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data
Author(s): Brendan Boyce, Lianping Xing
Proceedingsp. 1707
miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma
Author(s): Krishan Jethwa, Jun Wei, Kayla McEnery & Amy B Heimberger
Review Articlep. 1717
Boceprevir in the treatment of hepatitis C infection: rationale and clinical data
Author(s): Omer Khalid ,Bruce R Bacon
